肺癌,靶向及免疫治疗药物汇总表(2022年1月)

2022-01-01 e药安全 网络

肺癌,靶向及免疫治疗药物汇总表(2022年1月)

2021年底《国家基本医疗保险、工伤保险和生育保险药品目录(2021年)》公布,新版医保目录已于2022年1月1日起在全国范围内正式启用。2021年最新的医保目录中,新纳入多种抗肿瘤药物,覆盖范围颇广,包括非小细胞肺癌、淋巴瘤、乳腺癌、卵巢癌、肝癌、胃癌、骨髓瘤、前列腺癌、神经内分泌瘤等多癌种。对患者们来说,又有很多病友们等到了救命新药!

小编整理了在肺癌靶向、免疫治疗领域,经FDA、NMPA获批及NCCN指南推荐的40余个药物(截止2021年12月),并附医保支付价格及医保适应症等相关信息。供大家参看!

非小细胞肺癌

小细胞肺癌

备注:

1. FDA:美国食品药品监督管理局 NMPA:中国药品监督管理局 MHLW:日本厚生劳动省

2. 医保支付价格来源浙江省医保药品目录,援助方案及费用来源网络;若有错误欢迎留言指正。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-11 lexi Liao

    感谢总结

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-08 1e1ad8bdm04(暂无匿称)

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-04 1009312_2536

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-03 拉拉扯扯123

    学习了!谢谢

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1921861, encodeId=bc1a192186116, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Jan 10 10:11:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29071, encryptionId=fc9a290e1cb, topicName=免疫治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Apr 26 09:11:11 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183041, encodeId=7d111183041ca, content=感谢总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:10:33 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182240, encodeId=10661182240e4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Sat Jan 08 16:14:07 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180240, encodeId=63361180240f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ad06312481, createdName=1009312_2536, createdTime=Tue Jan 04 00:28:31 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180224, encodeId=4054118022427, content=学习了!谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bbe5562153, createdName=拉拉扯扯123, createdTime=Mon Jan 03 23:27:32 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180222, encodeId=6393118022255, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Jan 03 23:23:55 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-03 医鸣惊人

    认真学习了

    0

相关资讯

Radiology:深度学习预测临床I期非小细胞肺癌N2转移和生存

深度学习特征能准确预测临床I期非小细胞肺癌N2期病变及预后分层

JCO:3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后

吉非替尼辅助治疗可防止非小细胞肺癌早期复发,但并不能延长无病生存期或总生存期

中国非小细胞肺癌放射治疗临床指南(2020版)

中国非小细胞肺癌放射治疗临床指南(2020版)

Nature:非小细胞肺癌新靶点CLIP1-LTK被发现,劳拉替尼效果不错

据全球数据统计,在所有类型的癌症中,肺癌的死亡率最高,占癌症相关死亡的19%,占全球总死亡的3%。而非小细胞肺癌(NSCLC)约占肺癌总数的85%,是最常见的肺癌类型。